Current treatment of AL-CM ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 28 | Systemic amyloidosis | 1 |
28. Systemic amyloidosis
Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04924998 (ClinicalTrials.gov) | June 1, 2021 | 7/6/2021 | Clinical Study for AL-CM | Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy | Immunoglobulin Light Amyloidosis Cardiomyopathy | Drug: current treatment of AL-CM | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Recruiting | 18 Years | 80 Years | All | 400 | China |